Beddhu Srinivasan, Bastacky Sheldon, Johnson John P
Department of Medicine, University of Pittsburgh Medical Center, Pennsylvania, USA.
Medicine (Baltimore). 2002 Sep;81(5):398-409. doi: 10.1097/00005792-200209000-00005.
We review the clinical and histologic features of 17 patients with cryoglobulinemia and renal disease. Most cases were associated with evidence of hepatitis C virus (HCV), although a significant minority had no evidence of HCV. The most common histologic pattern for renal involvement was membranoproliferative glomerulonephritis, which was seen in both HCV-positive and HVC-negative patients. Clinical presentation was variable, including nephrotic syndrome, unexplained elevations of serum creatinine, acute renal failure, or extrarenal manifestations. All patients had type II or type III cryoglobulins and all had low serum complements at presentation. Liver function abnormalities in HCV-positive patients were mild. No clinical or laboratory features beyond hepatitis serologies were helpful in distinguishing between HCV-positive and HCV-negative patients. All but 1 HCV-positive patient were treated with interferon (IFN) in either standard or high dosage, and this treatment was largely ineffective. Five of 11 HCV-positive patients progressed to renal failure. HCV patients treated with cyclophosphamide did not develop active liver disease. In all HCV-negative patients, renal function stabilized or improved, and 5 of 6 were treated with cyclophosphamide. In our series, there is limited experience with IFN-ribavirin therapy, which was not well tolerated. Renal cryoglobulinemia is an uncommon illness of diverse etiologies and clinical presentations. Morphologic presentation is also varied. IFN alone is often inadequate therapy for HCV-associated cryoglobulinemia. Experience with IFN-ribavirin in this entity is limited, but has shown promise in hepatic disease and has shown efficacy in HCV-associated cryoglobulinemia. Cyclophosphamide is the treatment of choice for HCV-negative patients and can be used safely in most HCV-positive patients if they fail IFN or IFN-ribavirin therapy, or if they require more aggressive therapy during periods of rapid clinical progression.
我们回顾了17例冷球蛋白血症合并肾脏疾病患者的临床和组织学特征。大多数病例有丙型肝炎病毒(HCV)感染证据,尽管有相当少数病例无HCV感染证据。肾脏受累最常见的组织学类型是膜增生性肾小球肾炎,在HCV阳性和HCV阴性患者中均可见到。临床表现多样,包括肾病综合征、血清肌酐不明原因升高、急性肾衰竭或肾外表现。所有患者均有II型或III型冷球蛋白,且就诊时血清补体均降低。HCV阳性患者肝功能异常较轻。除肝炎血清学指标外,没有其他临床或实验室特征有助于区分HCV阳性和HCV阴性患者。除1例HCV阳性患者外,所有患者均接受了标准剂量或高剂量干扰素(IFN)治疗,但该治疗大多无效。11例HCV阳性患者中有5例进展为肾衰竭。接受环磷酰胺治疗的HCV患者未出现活动性肝病。所有HCV阴性患者肾功能稳定或改善,6例中有5例接受了环磷酰胺治疗。在我们的系列研究中,IFN-利巴韦林治疗经验有限,且耐受性不佳。肾冷球蛋白血症是一种病因和临床表现多样的罕见疾病。形态学表现也各不相同。单独使用IFN治疗HCV相关冷球蛋白血症往往不足。IFN-利巴韦林在该疾病中的经验有限,但在肝病方面已显示出前景,在HCV相关冷球蛋白血症中也已显示出疗效。环磷酰胺是HCV阴性患者的首选治疗药物,如果HCV阳性患者IFN或IFN-利巴韦林治疗失败,或者在临床快速进展期需要更积极的治疗,可以在大多数患者中安全使用。